OnKure Therapeutics, Inc. 10-Q

Item 5. Other Information No officers or directors, as defined in Rule 16a-1(f), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement,” as defined in Regulation S-K Item 408, during the last fiscal quarter. 84 Item 6. Exhibits EXHIBIT INDEX Incorporated by Reference Exhibit Number Description Form Filing Date Number Filed Herewith 2.1 Agreement and Plan of Merger, dated May 10, 2024, by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC and OnKure, Inc . 8-K 5/13/2024 2.1 3.1 Amended and Restated Certificate of Incorporation, as amended. 8-K 10/8/2024 3.2 3.2 Amended and Restated Bylaws . 8-K 10/8/2024 3.3 4.1 Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated December 9, 2020. S-1 3/19/2021 4.2 31.1 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 31.2 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. X 32.1 † Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. X 101. INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema Document X 85 Exhibit Number Description Form Filing Date Number Filed Herewith 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). X † This certification shall not be deemed filed for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act. 86 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: May 6, 2025 ONKURE THERAPEUTICS, INC. By: /s/ Nicholas A. Saccomano, Ph.D. Name: Nicholas A. Saccomano, Ph.D. Title: President and Chief Executive Officer (Principal Executive Officer) By: /s/ Jason Leverone Name: Jason Leverone Title: Chief Financial Officer (Principal Financial and Accounting Officer) 87